1.Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G: Hepatocellular carcinoma. Nat Rev Dis Primers 2016, 2:16018.
2.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015, 65(2):87–108.
3.Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J et al: Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget 2017, 8(33):55715–55730.
4.Bruix J, Sherman M, American Association for the Study of Liver D: Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020–1022.
5.Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012, 379(9822):1245–1255.
6.Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34(2):122–136.
7.Ferraris GM, Sidenius N: Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. Semin Thromb Hemost 2013, 39(4):347–355.
8.Mahmood N, Mihalcioiu C, Rabbani SA: Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol 2018, 8:24.
9.Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC et al: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000, 60(3):636–643.
10.Ljuca D, Fatusic Z, Iljazovic E, Ahmetovic B: Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn J Basic Med Sci 2007, 7(2):111–116.
11.Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J: Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev 2011, 20(4):609–618.
12.Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB: Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000, 126(11):641–646.
13.Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P, Dano K: Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988, 111(1):42–51.
14.Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ et al: Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 2010, 102(4):731–737.
15.Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM: Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007, 25(4):349–355.
16.Zhang W, Ling D, Tan J, Zhang J, Li L: Expression of urokinase plasminogen activator and plasminogen activator inhibitor type–1 in ovarian cancer and its clinical significance. Oncol Rep 2013, 29(2):637–645.
17.Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, De Paoli M, Plebani M, Tulassay Z: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type–1, CEA and CA 19–9 in colorectal cancer. BMC Cancer 2008, 8:194.
18.Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR: Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19–9 and carcinoembryonic antigen. Cancer Res 1993, 53(8):1788–1793.
19.Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S: Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999, 39(2):123–129.
20.Herszenyi L, Istvan G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F: Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 2008, 17(5):438–445.
21.Wei L, Lun Y, Zhou X, He S, Gao L, Liu Y, He Z, Li B, Wang C: Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacol Res 2019, 143:73–85.
22.Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ: The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep 2017, 7(1):12870.
23.Sanchez AIP, Roces LV, Garcia IZ, Lopez EL, Hernandez MAC, Parejo MIB, Pena-Diaz J: Value of alpha-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018, 15(6):8863–8870.
24.Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J et al: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006, 132(7):458–465.
25.Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnu L, Zoli M et al: Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012, 56(4):1371–1379.
26.Lee YA, Wallace MC, Friedman SL: Pathobiology of liver fibrosis: a translational success story. Gut 2015, 64(5):830–841.
27.Hernandez-Gea V, Friedman SL: Pathogenesis of liver fibrosis. Annual review of pathology 2011, 6:425–456.
28.Leyland H, Gentry J, Arthur MJ, Benyon RC: The plasminogen-activating system in hepatic stellate cells. Hepatology 1996, 24(5):1172–1178.
29.Bezerra JA, Currier AR, Melin-Aldana H, Sabla G, Bugge TH, Kombrinck KW, Degen JL: Plasminogen activators direct reorganization of the liver lobule after acute injury. Am J Pathol 2001, 158(3):921–929.
30.Shanmukhappa K, Sabla GE, Degen JL, Bezerra JA: Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor. BMC Gastroenterol 2006, 6:40.
31.Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC et al: A noninvasive diagnosis of hepatic fibrosis by BioFibroScore(R) in chronic hepatitis C patients. J Gastroenterol Hepatol 2018, 33(1):291–297.
32.He C, Zhou Z, Xiao Z, Wang J: Treatment strategy for huge hepatocellular carcinoma with intrahepatic metastasis and macrovascular invasion: a case report and literature review. J Cancer Res Ther 2018, 14(Supplement):S1233-S1236.